COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Endometrial Effects of Daily Progesterone s.c. 25 and 50 Mg Aqueous Formulation to Female Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00377923
Recruitment Status : Completed
First Posted : September 19, 2006
Last Update Posted : September 20, 2006
Information provided by:
IBSA Institut Biochimique SA

Brief Summary:
This is a multiple dose, observer blind, randomised, parallel groups pharmacodynamic and pharmacokinetic study to assess the endometrial effects (predecidual changes) of a new aqueous progesterone formulation administered s.c. at the dose of 25 and 50 mg/day.

Condition or disease Intervention/treatment Phase
Healthy Drug: Progesterone Phase 1

Detailed Description:

This study is designed in order to assess the efficacy of the investigational product (Progesterone acqueous s.c. formulation) when it is administered at the dose of 25 and 50 mg. The induced predecidual changes will be evaluated through endometrial bioptic samplings, performed on day 11 and will be compared between the two treatment groups.

The pharmacokinetic evaluation was designed according to internationally recognised guidelines for PK studies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Study Start Date : August 2005
Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. partial and full predecidual changes in endometrial samples on the 11th day of exposure to the IMP compared to the findings on the 11th day after ovulation in the menstrual cycle, according to Noyes criteria

Secondary Outcome Measures :
  1. PK profile of progesterone at the steady-state following the 25 or 50 mg/day of progesterone s.c. at the time of endometrial biopsy, local tolerability

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI: 19</=BMI</=25 kg/m2;
  • Proper estrogen priming; absence of progesterone exposure prior to exogenous progesterone administration;
  • normal pelvic ultrasound;
  • absence of active follicular growth following initiation of E2 treatment;
  • Complete suppression of ovarian function;
  • Vital signs: SBP 100-139 mmHg, DBP 50-89, HR 50-90 bpm;
  • Full comprehension of the nature and purpose of the study and possible risks and side effects;
  • signed written informed consent prior to inclusion in the study

Exclusion Criteria:

  • pregnant or lactating women;
  • ECG: clinically relevant abnormalities;
  • clinical relevant abnormal physical findings which could interfere with the objectives of the study;
  • clinical relevant abnormal laboratory values indicative of physical illness, ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients;
  • history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study;
  • history of uterine pathologies (fibroids, polyps, adenomyosis, etc), history of dysfunctional bleeding, relevant history of renal, hepatic, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases, history of neoplasias (genital apparatus, breast, liver or hormone-dependent cancer) severe liver failure, acute or chronic liver dysfunction, cholestatic jaundice, hypertension, thrombo-phlebitis, thrombo-embolism, cerebro-vascular insult or severe depression; medication, including OTC, during 2 weeks before the start of the study;
  • participation in the evaluation of any drug within 1 month prior to the start of the study;
  • blood donations during the 1 month prior to this study;
  • history of drug, alcohol [>1 drink/day defined according to USDA Dietary Guidelines 2005 (18)] caffeine (>5 cups/ day of coffee or tea) or tobacco abuse (≥10 cigarettes/day);
  • Abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits within the past 4 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00377923

Sponsors and Collaborators
IBSA Institut Biochimique SA
Layout table for investigator information
Principal Investigator: Markus Müller, Prof Department of Clinical Pharmacology, AKH, Vienna, Austria.

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00377923    
Other Study ID Numbers: 05A/Prg05
First Posted: September 19, 2006    Key Record Dates
Last Update Posted: September 20, 2006
Last Verified: September 2006
Keywords provided by IBSA Institut Biochimique SA:
pharmacodynamic and pharmacokinetic study
healthy volunteers
Endometrial decidualisation
Additional relevant MeSH terms:
Layout table for MeSH terms
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs